EXP001973

Paper

Self-Assembling Peptide-Based Nanoparticles for siRNA Delivery in Primary Cell Lines (2012)

Peptide

Sequence: Ac-GLWRALWRLLRSLWRLLWKA-cya

RNA

All experiment fields

Experiment Id	EXP001973
Paper	Self-Assembling Peptide-Based Nanoparticles for siRNA Delivery in Primary Cell Lines
Peptide	CADY
Delivery Success Class	no
In Vivo Flag	no
Uptake Confirmed	no
Label Confidence	high
In Vitro Functional Effect	yes
Endosomal Escape Evidence
Peptide Concentration	Peptide amount defined by molar ratio to siRNA (20:1 or 40:1). Complexes prepared at 100 nM siRNA then diluted to desired siRNA dose while maintaining ratio.
Rna Concentration	Dose–response 0.125–20 nM siRNA (mRNA measured 12 h post-transfection in serum-containing medium).
Mixing Ratio	CADY:siRNA molar ratio 20:1 or 40:1 (10:1 unstable; 5:1 unstable). Stock complexes often prepared with 100 nM siRNA, 30 min at 37°C, then diluted to 0.125–20 nM keeping ratio constant.
Formulation Format	Self-assembling peptide/siRNA nanoparticles (noncovalent electrostatic + hydrophobic interactions)
Formulation Components	CADY peptide complexed with GAPDH siRNA; complexes formed in water then diluted in 0.5× PBS / serum-containing culture medium.
Size Nm	156.00
Zeta Mv	46.00
Model Scope	in_vitro
Model Type	in vitro
Cell Lines Or Primary Cells	Jurkat T lymphocytes (suspension T cell line; challenging to transfect)
Animal Model
Administration Route
Output Type	In vitro functional RNA effect: GAPDH mRNA knockdown (Quantigene) ± IC50; toxicity by MTT/cyclophilin B mRNA
Output Value	>85% GAPDH mRNA reduction achieved at 20 nM siRNA (20:1 or 40:1); estimated IC50 ≈ 1.2 ± 0.1 nM
Output Units
Output Notes	Efficient silencing in serum-containing medium; 10:1 ratio shows poor response due to particle instability.
Toxicity Notes	No significant toxicity reported; cell viability >85% across tested siRNA doses and CADY concentrations (up to ~200 nM siRNA complex; 1–4 µM CADY).
Curation Notes